Randomized study evaluating the impact of an innovative and cooperative pathway integrating oncogeriatric, pharmaceutical and pharmacological follow-up in elderly patients (>70 years old) presenting with cancer and treated with oral therapy_POG

Prior treatment

• Patient who has already been treated or is currently being treated with the oral therapy studied
• Patient who has already benefited from a pharmacological dosage for the oral therapy studied
• Presence of a pathology or condition that makes the patient's participation in the study inappropriate, which includes serious unresolved or unstable toxicities from previous administration of another investigational treatment or any medical condition that could interfere with the patient safety, obtaining consent, or compliance with study procedures

Other illness

• Mental or psychological illness that does not allow the patient to give informed consent

Other

• Grade 3 or 4 toxicity contraindicating the implementation of oral treatment, according to the NCI-CTCAE version 6.0
• Patient unable to follow the therapeutic program
• Patient who has already benefited from specialized oncogeriatric care in the last 12 months
• Patient under guardianship or deprived of his liberty by a judicial or administrative decision or incapable of giving its consent

• Age ≥ 70 years old
• Patients must be affiliated to a social security system or beneficiary of the same
• G8 score ≤14
• PS ≤ 3
• Follow-up for a locally advanced or metastatic solid tumor among the following: • Breast Cohort • Lung Cohort • Prostate cohort • Colon Cohort • Kidney Cohort • Sarcoma/GIST cohort
• With a decision to initiate treatment with oral therapy (Tyrosine Kinase Inhibitor, Hormone Therapy) from among the following: • Breast cohort: Abemaciclib, Ribociclib, Palbociclib, Everolimus • Lung cohort: Alectinib, Brigatinib, Osimertinib • Prostate cohort: Abiraterone, Enzalutamide, Olaparib • Colon cohort: Trifluridine + Tipiracil, Capecitabine • Kidney cohort: Axitinib, Cabozantinib, Lenvatinib • Sarcoma/ GIST cohort: Sunitinib, Regorafenib, Pazopanib
• Female patients must either be of non-reproductive potential or must have a negative serum pregnancy test within 14 days prior to the administration of study drug. Childbearing potential women must have agreed to use one barrier method of contraception, such as condom, plus an additional highly effective method of contraception during treatment on this trial an for up to 6 month after the last dose of study treatment.
• Sexually active males patients must agree to use condom during the clinical investigation and for at least 6 months after the study treatment. Also, it is recommended the childbearing potential female partner uses a highly effective method of contraception for the same duration (cf. paragraph 7.8 « Pregnancy and contraception »)
• Written, dated and signed informed consent by the patient prior to any specific protocol procedure
• Ability to comply with the protocol procedures